Skip to main content
Publications
Hamadani M, Spira AI, Zhou X, Liao L, Chen L, Radford J, Ai WZ, Solh MM, Ardeshna KM, Hess BT, Caimi PF, Stathis A, Carlo Stella C, Alderuccio JP, Kahl BS, Wang Y, Qin YG, Xu ZC, Zinzani PL. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Blood Adv. 2024 Jan;9(1):93-8. doi: 10.1182/bloodadvances.2023010636
Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jimenez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martinez-Lopez J, Wang Y, Link BK. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022 Nov 22;6(22):5835-43. doi: 10.1182/bloodadvances.2022008150
Ribera A, Gimenez E, Oristrell G, Osorio D, Marsal JR, Garcia-Perez L, Ballesteros M, Rodenas E, Belahnech Y, Escalona R, Rivas N, Roca-Luque I, Ferreira-Gonzalez I, Espallargues M. Cost-effectiveness of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. Rev Esp Cardiol (Engl Ed). 2022 Jan;75(1):12-21. doi: 10.1016/j.rec.2021.05.004
Galian-Gay L, Gordon B, Marsal JR, Rafecas A, Pijuan Domenech A, Castro MA, Subirana Domenech MT, Sureda C, Miranda B, Marti G, Garcia-Dorado D, Dos Subira L. Determinants of long-term outcome of repaired pulmonary valve stenosis. Rev Esp Cardiol (Engl Ed). 2020 Feb;73(2):131-8.